<description>&lt;p&gt;In this BTOG podcast, Dr Tom Newsom-Davis, Chair of BTOG and Consultant Thoracic Medical Oncologist at Chelsea and Westminster Hospital, is joined by Dr Joanne Evans, Consultant in Medical Oncology at Imperial College Healthcare NHS Trust, and Adam Januszewski, Consultant Medical Oncologist at St Bartholomew’s Hospital, to discuss key lung cancer highlights from ASCO 2026.&lt;/p&gt;&lt;p&gt;The panel reviews major data across advanced and early-stage lung cancer, including HARMONi-6, WUKONG-28, ALKOVE-1, OPTITROP-Lung05 and LORIN, as well as updates from CROWN, LIBRETTO-432, CHRYSALIS-2 and DELLphi-304.&lt;/p&gt;&lt;p&gt;Topics include emerging antibody-drug conjugates, targeted treatments for EGFR exon 20 insertions, ALK-positive disease, perioperative therapy, atypical EGFR mutations, RET-positive disease and CNS activity in small cell lung cancer.&lt;/p&gt;&lt;p&gt;The discussion considers what the data may mean for UK practice, where further global evidence is needed, and how efficacy, toxicity and patient selection should shape future treatment decisions.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;
</description>

In this BTOG podcast, Dr Tom Newsom-Davis, Chair of BTOG and Consultant Thoracic Medical Oncologist at Chelsea and Westminster Hospital, is joined by Dr Joanne Evans, Consultant in Medical Oncology at Imperial College Healthcare NHS Trust, and Adam Januszewski, Consultant Medical Oncologist at St Bartholomew’s Hospital, to discuss key lung cancer highlights from ASCO 2026.The panel reviews major data across advanced and early-stage lung cancer, including HARMONi-6, WUKONG-28, ALKOVE-1, OPTITROP-Lung05 and LORIN, as well as updates from CROWN, LIBRETTO-432, CHRYSALIS-2 and DELLphi-304.Topics include emerging antibody-drug conjugates, targeted treatments for EGFR exon 20 insertions, ALK-positive disease, perioperative therapy, atypical EGFR mutations, RET-positive disease and CNS activity in small cell lung cancer.The discussion considers what the data may mean for UK practice, where further global evidence is needed, and how efficacy, toxicity and patient selection should shape future treatment decisions.

BTOG - British Thoracic Oncology Group

BTOG ASCO 2026 Update with Tom Newsom-Davis, Joanne Evans and Adam Januszewski

BTOG ASCO 2026 Update with Tom Newsom-Davis, Joanne Evans and Adam Januszewski

Description